Apply imaging and lab features to visualize the Management Pathway.
Guidelines & Evidence
Clinical Details
Section 1
When to Use
When to Use
Management of suspected Intraductal Papillary Mucinous Neoplasms (IPMNs)
To differentiate between Branch Duct (BD), Main Duct (MD), and Mixed-Type IPMNs
To guide the decision for surgical resection vs. surveillance vs. EUS exploration
Target Population
Adults with mucinous pancreatic cysts identified on CT or MRI. The 2017 Fukuoka update (Revision of the 2012 Consensus) is currently the standard-of-care reference for high-sensitivity screening.
Section 2
Formula & Logic
High-Risk Stigmata (Surgical Referral)
Obstructive jaundice in a patient with a pancreatic head cyst
Enhancing solid component/mural nodule ≥ 5 mm
Main pancreatic duct (MPD) diameter ≥ 10 mm
Worrisome Features (EUS/FNA Referral)
Cyst size ≥ 3 cm
Enhancing mural nodule < 5 mm
Thickened/enhancing cyst walls
Main pancreatic duct diameter 5–9 mm
Abrupt change in MPD caliber with distal atrophy
Lymphadenopathy
Rapid cyst growth (> 5 mm in 2 years)
Surveillance Intervals (BD-IPMN)
< 1 cm
CT/MRI in 6 months, then every 2 years
1–2 cm
CT/MRI every 1 year for 2 years, then every 2 years
2–3 cm
EUS in 6 months, then CT/MRI alternating 6-12 months
> 3 cm
Close surveillance or surgery (if other features)
Section 3
Pearls/Pitfalls
Fukuoka vs. AGA (2015)
The Fukuoka criteria are significantly more sensitive (and thus more aggressive) than the AGA 2015 criteria. Fukuoka prioritizes missing zero cancers, whereas AGA prioritizes reducing the morbidity of unnecessary surgeries. Experts generally favor Fukuoka for young, fit patients.
Main Duct (MD) Risk
Any MD-IPMN (duct > 10 mm) carries a 60% risk of malignancy over the patient's lifetime. Surgical resection is almost universally recommended for true MD-IPMN in surgical candidates.
Clinical Pearls
Cyst fluid CEA > 192 ng/mL confirms a "mucinous" cyst but does not predict malignancy
Cyst fluid Glucose < 50 mg/dL is a highly accurate marker for mucinous vs. non-mucinous cysts (superior to CEA in some studies)
Surveillance discontinuation should only be considered in elderly patients with low life expectancy or clinically stable low-risk cysts < 1 cm
Section 4
Next Steps
Clinical Decision Tree
01
Any High-Risk Stigmata: Refer to Pancreatic Surgeon.
02
Any Worrisome Feature: Refer for EUS-FNA to look for mural nodules or HGD cytology.
03
No Features: Routine MRI surveillance.
Complementary Scoring
AGA Pancreatic Cyst Guidelines
Rosemont Criteria (EUS Pancreatitis)
Ca 19-9 Interpretation
Section 5
Evidence Appraisal
The 2017 Revision
Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas.
Tanaka M et al. • Pancreatology. 2017;17(5):738-753. The current gold-standard reference.
The International Association of Pancreatology (IAP)
First established at a meeting in Sendai (2006) and subsequently refined in Fukuoka (2012), the guidelines were created by a global panel of experts from Japan, the US, and Europe to address the explosion of incidentally detected pancreatic cysts.
